LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Novus Biologicals | Catalog # NBP2-22114

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Rat

Cited:

Human, Mouse, Rat

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, ELISA, Flow Cytometry

Cited:

Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, IF/IHC

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 7F6

Format

BSA Free
View all LAP (TGF-beta 1) Primary Antibodies »

Product Specifications

Immunogen

Purified recombinant fragment of human TGF beta 1 (amino acids 62-197) expressed in E. coli. [UniProt# P01137]

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 26851347). Rat reactivity reported in scientific literature (PMID: 30147399).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

44.3 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6)BSA Free [NBP2-22114]

Western Blot: LAP (TGF-beta 1) Antibody (7F6)BSA Free [NBP2-22114]

Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)
Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lymphoid tissue tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.
Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Flow cytometric analysis of A549 cells using LAP (TGF-beta 1) mouse mAb (green) and negative control (red).
Western Blot: LAP (TGF-beta 1) Antibody (7F6)BSA Free [NBP2-22114]

Western Blot: LAP (TGF-beta 1) Antibody (7F6)BSA Free [NBP2-22114]

Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis of human stomach tissue (A) and human small intestine tissue (B) using TGF beta 1 antibody (NBP2-22114) at 2 ug/ml.
Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Human tonsil. Image from verified customer review.
Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lung cancer tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.
ELISA: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

ELISA: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114]

ELISA: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

CD47 regulates thrombospondin-1, TGF-beta 1, and collagen deposition after injury. a Whole cell lysates from freshly isolated intestinal epithelial cells from Cd47f/f and Cd47 delta IEC mice were subjected to SDS–PAGE and immunoblot for thrombospondin-1/TSP-1, TGF-beta 1, and phosphorylated SMAD2 and SMAD3. Results are representative of three independent experiments. b Representative Masson’s trichrome staining of wounds beds and chronic DSS-colitis colons from Cd47f/f and Cd47 delta IEC mice. Scale bars = 50 μm. Results representative of three independent experiments with 5–7 mice per group. Source data are provided as a Source Data file Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31676794), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

Inhibition of ERK1/2 activation attenuates myocardial remodeling and inflammation in permanent MI.Trametinib- and vehicle-treated mice were studied for 7 days after permanent LAD ligation. (A) Relative mRNA expression analysis of Il6, Tnf, Ccl2, and Ccr2 from the infarcted myocardium. (B) Flow cytometry analysis of the infarcted myocardium obtained from vehicle- or trametinib-treated mice normalized to heart weight. Representative gating strategies for quantification of CD45+ leukocytes: CD45+CD90.2–B220–NK1.1–CD11b+ myelomonocytic cells, CD45+CD90.2–B220–NK1.1–CD11b+Ly6G–F4/80–Ly6Chi monocytes, and CD45+CD90.2–B220–NK1.1–CD11b+Ly6G–F4/80–Ly6Clo macrophages. (C) Protein expression analysis of p-ERK1/2 (normalized to total ERK1/2) and activated TGF-beta 1 (normalized to GAPDH) in infarcted myocardium obtained from vehicle- or trametinib-treated mice. IOD, integrated optical density. (D) Protein expression analysis of p-ERK1/2 (normalized to ERK1/2) and activated TGF-beta 1 (normalized to GAPDH) in PBMCs isolated from vehicle- or trametinib-treated mice. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 4–6 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

Inhibition of ERK1/2 activation attenuates myocardial remodeling and inflammation in permanent MI.Trametinib- and vehicle-treated mice were studied for 7 days after permanent LAD ligation. (A) Relative mRNA expression analysis of Il6, Tnf, Ccl2, and Ccr2 from the infarcted myocardium. (B) Flow cytometry analysis of the infarcted myocardium obtained from vehicle- or trametinib-treated mice normalized to heart weight. Representative gating strategies for quantification of CD45+ leukocytes: CD45+CD90.2–B220–NK1.1–CD11b+ myelomonocytic cells, CD45+CD90.2–B220–NK1.1–CD11b+Ly6G–F4/80–Ly6Chi monocytes, and CD45+CD90.2–B220–NK1.1–CD11b+Ly6G–F4/80–Ly6Clo macrophages. (C) Protein expression analysis of p-ERK1/2 (normalized to total ERK1/2) and activated TGF-beta 1 (normalized to GAPDH) in infarcted myocardium obtained from vehicle- or trametinib-treated mice. IOD, integrated optical density. (D) Protein expression analysis of p-ERK1/2 (normalized to ERK1/2) and activated TGF-beta 1 (normalized to GAPDH) in PBMCs isolated from vehicle- or trametinib-treated mice. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 4–6 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

The upregulation of TGF beta 1/IGF-1/BDNF expression in the brain of AD mice by PBMT extended to promote adult hippocampal neurogenesis. A, B Western blotting analysis (A) and quantification (B) of TGF beta 1/IGF-1/BDNF expression in APP/PS1 and 3xTg-AD mouse brain after PBMT, (n = 3–4 per group). C The concentration of TGF beta 1/IGF-1/BDNF in brain tissues were measured by enzyme linked immunosorbent assay (ELISA), (n = 3–6 per group). D Representative images of Nestin+ (neural stem cell staining) and neuronal class-III beta -tubulin (Tuj1)+ (newborn neurons staining) expression cells in APP/PS1 and 3xTg-AD mouse hippocampal dentate gyrus (DG) at the end of PBMT. Scale bars, 50 μm. E Quantitative analyses of Nestin+ and Tuj1+ area in the hippocampal DG of each group, (n = 4 per group). F Quantitative analyses of the Nestin and Tuj1 mean fluorescence (MFI) in the brain tissues of each group after PBMT. The Nestin and Tuj1 MFI were detected by flow cytometer, (n = 5–6 per group). G Tuj1 antibody was used to staining the newborn neurons, and then, the expression of alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPAR) and postsynaptic density protein 95 (PSD95) on Tuj1+ neurons were detected by flow cytometer. All quantifications are presented as mean +/- SEM and were analyzed by one-way ANOVA test; ***p < 0.001, **p < 0.01, *p < 0.05 versus WT group; ###p < 0.001, ##p < 0.01, #p < 0.05 versus indicated group Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36217178), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

TF cytoplasmic domain phosphorylation–dependent increased TGF-beta 1 activation in clinical setting of MI.(A) Representative confocal images of phosphorylation status of TF in infarcted myocardium obtained from WT or TF delta CT mice after 7 days. Representative images and quantification of biological replicates. Kruskal-Wallis test and Dunn’s multiple-comparison test; n = 3–4 animals per group. Scale bars: 50 μm. (B) Representative immunofluorescence confocal microscopy images of CD45+ and CD45/p-TF double-positive cells in human myocardium specimens obtained from n = 5 nonischemic (NI) donor hearts and n = 7 IHF patients. Quantification of biological replicates. Mann-Whitney test. Scale bars: 50 μm. (C and D) Western blot analysis and quantification of human LV tissue obtained from n = 5 nonischemic donor hearts and n = 9 IHF patients for p-TF (normalized to total TF) and TF (C) or TGF-beta 1 (normalized to GAPDH) and p-SMAD2 (normalized to total SMAD2) (D). Mann-Whitney test. Data are shown as mean +/- SEM. *P < 0.05. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

A profibrotic MEK1/2–TGF-beta 1 pathway is linked to PAR2-mediated ROS signaling in monocytes.(A and B) Protein expression analysis of monocytes isolated from WT mice and pretreated in vitro with trametinib (10 μM) for 1 hour (A), or isolated from PAR2–/– versus WT mice (B). Cells were stimulated with an inflammatory cytokine cocktail containing IL-6, TNF-alpha, and CCL2 at a concentration of 20 ng/mL with and without hypoxia for 4 hours. Western blotting of p-ERK1/2 (normalized to total ERK1/2) and activated TGF-beta 1 (normalized to GAPDH). Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5 replicates (2–3 mice were pooled for each sample). (C–E) PAR2fl/fl and PAR2fl/fl LysMCre littermates were subjected to permanent LAD ligation and investigated after 7 days; n = 5–10 animals per group. (C) Western blot analysis of activated TGF-beta 1 (normalized to GAPDH) and p-SMAD2 (normalized to total SMAD2) in the infarcted myocardium. Representative blots and quantification of biological replicates. (D) High-frequency ultrasound echocardiography obtained from PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice with measurement of LVEF (%) and LVEDV (μL). Mann-Whitney test. (E) Kaplan-Meier survival analysis of permanently LAD-ligated PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice over 7 days. Log-rank (Mantel-Cox) test. (F) Sirius red staining and deconvoluted images of fibrotic area on paraffin-embedded heart sections 4 weeks after permanent LAD ligation to induce IHF. Representative images and quantification of fibrotic areas normalized to surface area. Unpaired, 2-sided t test; n = 5 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

A profibrotic MEK1/2–TGF-beta 1 pathway is linked to PAR2-mediated ROS signaling in monocytes.(A and B) Protein expression analysis of monocytes isolated from WT mice and pretreated in vitro with trametinib (10 μM) for 1 hour (A), or isolated from PAR2–/– versus WT mice (B). Cells were stimulated with an inflammatory cytokine cocktail containing IL-6, TNF-alpha, and CCL2 at a concentration of 20 ng/mL with and without hypoxia for 4 hours. Western blotting of p-ERK1/2 (normalized to total ERK1/2) and activated TGF-beta 1 (normalized to GAPDH). Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5 replicates (2–3 mice were pooled for each sample). (C–E) PAR2fl/fl and PAR2fl/fl LysMCre littermates were subjected to permanent LAD ligation and investigated after 7 days; n = 5–10 animals per group. (C) Western blot analysis of activated TGF-beta 1 (normalized to GAPDH) and p-SMAD2 (normalized to total SMAD2) in the infarcted myocardium. Representative blots and quantification of biological replicates. (D) High-frequency ultrasound echocardiography obtained from PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice with measurement of LVEF (%) and LVEDV (μL). Mann-Whitney test. (E) Kaplan-Meier survival analysis of permanently LAD-ligated PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice over 7 days. Log-rank (Mantel-Cox) test. (F) Sirius red staining and deconvoluted images of fibrotic area on paraffin-embedded heart sections 4 weeks after permanent LAD ligation to induce IHF. Representative images and quantification of fibrotic areas normalized to surface area. Unpaired, 2-sided t test; n = 5 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

Myeloid cell–derived TF-PAR2 complex is required for TGF-beta 1 activation.(A) Confocal microscopy of myocardial cryosections obtained from n = 5 sham-operated and n = 5 LAD-ligated WT (C57BL/6J) mice at day 7. Representative images and quantification of TF+ cells costained for CD45. Unpaired, 2-sided t test. Scale bar: 50 μm. (B–D) TFfl/fl LysMCre and TFfl/fl littermates were subjected to permanent LAD ligation versus sham surgery and investigated after 7 days; n = 5–7 animals per group. (B) Protein expression analysis of p-ERK1/2 (normalized to total ERK1/2) in the infarcted myocardium. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test. (C) Western blot analysis of activated TGF-beta 1 (normalized to GAPDH) and p-SMAD2 (normalized to total SMAD2) in the infarcted myocardium obtained from TFfl/fl LysMCre and TFfl/fl littermates. Representative blots and quantification of biological replicates. (D) High-frequency ultrasound echocardiography obtained from TFfl/fl LysMCre and TFfl/fl littermates. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test. (E) Sirius red staining and deconvoluted images of fibrotic area on paraffin-embedded heart sections 4 weeks after permanent LAD ligation to induce IHF versus sham surgery. Representative images and quantification of fibrotic areas normalized to surface area. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5 animals per group. (F) Kaplan-Meier survival analysis of permanently LAD-ligated TFfl/fl LysMCre and TFfl/fl littermate mice over 4 weeks. Log-rank (Mantel-Cox) test; n = 10–15 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

Myeloid cell TF cytoplasmic domain phosphorylation mediates ERK1/2–TGF-beta 1–dependent cardiac remodeling in permanent LAD ligation.(A) Confocal microscopy of myocardial cryosections obtained from WT (C57BL/6J) and TF delta CT mice. Representative images and quantification of MFI of Ly6C+TGF beta -1+ and CD31+TGF-beta 1+ cells. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5 animals per group. Scale bars: 25 μm. (B) Mice with transplanted BM were subjected to permanent LAD ligation versus sham surgery and investigated 7 days later. Western blot analysis of NOX2 (normalized to GAPDH), p-ERK1/2 (normalized to total ERK1/2), and TGF-beta 1 (normalized to GAPDH) in infarcted myocardium obtained from chimeric mice. Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5–7 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Western Blot: LAP (TGF-beta 1) Antibody (7F6) - BSA Free [NBP2-22114] -

A profibrotic MEK1/2–TGF-beta 1 pathway is linked to PAR2-mediated ROS signaling in monocytes.(A and B) Protein expression analysis of monocytes isolated from WT mice and pretreated in vitro with trametinib (10 μM) for 1 hour (A), or isolated from PAR2–/– versus WT mice (B). Cells were stimulated with an inflammatory cytokine cocktail containing IL-6, TNF-alpha, and CCL2 at a concentration of 20 ng/mL with and without hypoxia for 4 hours. Western blotting of p-ERK1/2 (normalized to total ERK1/2) and activated TGF-beta 1 (normalized to GAPDH). Ordinary 1-way ANOVA, Šidak’s multiple-comparison test; n = 5 replicates (2–3 mice were pooled for each sample). (C–E) PAR2fl/fl and PAR2fl/fl LysMCre littermates were subjected to permanent LAD ligation and investigated after 7 days; n = 5–10 animals per group. (C) Western blot analysis of activated TGF-beta 1 (normalized to GAPDH) and p-SMAD2 (normalized to total SMAD2) in the infarcted myocardium. Representative blots and quantification of biological replicates. (D) High-frequency ultrasound echocardiography obtained from PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice with measurement of LVEF (%) and LVEDV (μL). Mann-Whitney test. (E) Kaplan-Meier survival analysis of permanently LAD-ligated PAR2fl/fl LysMCre and PAR2fl/fl littermate control mice over 7 days. Log-rank (Mantel-Cox) test. (F) Sirius red staining and deconvoluted images of fibrotic area on paraffin-embedded heart sections 4 weeks after permanent LAD ligation to induce IHF. Representative images and quantification of fibrotic areas normalized to surface area. Unpaired, 2-sided t test; n = 5 animals per group. Data are shown as mean +/- SEM. *P < 0.05, **P < 0.01, ****P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36548062), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Application
Recommended Usage

ELISA

1:10000

Flow Cytometry

1:200-1:400

Immunohistochemistry

reported in scientific literature (PMID 30147399)

Immunohistochemistry-Paraffin

reported by customer review

Western Blot

1:500-1:2000

Reviewed Applications

Read 3 reviews rated 3.7 using NBP2-22114 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now
Flow Cytometry

Formulation, Preparation, and Storage

Purification

Ammonium sulfate precipitation

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: LAP (TGF-beta 1)

This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. Many cells have TGFB receptors, and the protein positively and negatively regulates many other growth factors. The secreted protein is cleaved into a latency-associated peptide (LAP) and a mature TGFB1 peptide, and is found in either a latent form composed of a TGFB1 homodimer, a LAP homodimer, and a latent TGFB1-binding protein, or in an active form composed of a TGFB1 homodimer. The mature peptide may also form heterodimers with other TGFB family members. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease

Long Name

Latency-associated Peptide

Alternate Names

LAP (TGFbeta 1)

Entrez Gene IDs

7040 (Human)

Gene Symbol

TGFB1

UniProt

P01137 (Human)

Additional LAP (TGF-beta 1) Products

Product Documents for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Customer Reviews for LAP (TGF-beta 1) Antibody (7F6) - BSA Free (3)

3.7 out of 5
3 Customer Ratings
5 Stars
33%
4 Stars
33%
3 Stars
0%
2 Stars
33%
1 Stars
0%

Have you used LAP (TGF-beta 1) Antibody (7F6) - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 3 of 3 reviews Showing All
Filter By:
Clear Filters X
  • LAP (TGF-beta 1) Antibody (7F6)
    Name: Shatovisha Dey
    Application: Western Blot
    Sample Tested: Mouse Pancreas
    Species: Mouse
    Verified Customer | Posted 10/02/2020
    Caerulein dosed mouse pancreas
    LAP (TGF-beta 1) Antibody (7F6) - BSA Free NBP2-22114
  • Name: Anonymous
    Application: Immunohistochemistry-Paraffin
    Sample Tested: Human kidney
    Species: Human
    Verified Customer | Posted 10/28/2015
  • Name: Hayley Derricott
    Application: Immunohistochemistry-Paraffin
    Sample Tested: human tonsil
    Species: Human
    Verified Customer | Posted 04/04/2014
    Human tonsil - TGF beta
    LAP (TGF-beta 1) Antibody (7F6) - BSA Free NBP2-22114

There are no reviews that match your criteria.

Showing  1 - 3 of 3 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for LAP (TGF-beta 1) Antibody (7F6) - BSA Free

Showing  1 - 1 of 1 FAQ Showing All

  • Q: Info regarding this product NBP2-22114SS, does this product cross reacts with Latent TGF-beta 1 also?

    A: Based on the immunogen sequence, we predict it would cross react.

Showing  1 - 1 of 1 FAQ Showing All
View all FAQs for Antibodies